<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100771</url>
  </required_header>
  <id_info>
    <org_study_id>DR210107</org_study_id>
    <nct_id>NCT05100771</nct_id>
  </id_info>
  <brief_title>Optimized Volumetry in Radiology: Interest in Pediatric Brain MRI in the Exploration of Focal Epilepsy</brief_title>
  <acronym>ORACLE</acronym>
  <official_title>Volumétrie Optimisée en Radiologie : intérêt en IRM Cérébrale pédiatrique Dans l'Exploration de l'épilepsie Focale</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre cross-sectional study with prospective recruitment comparing the detection rate&#xD;
      of lesions on brain MRI without and with quantitative volumetry and T1 relaxometry&#xD;
      information during the management of children with suspected focal epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Focal epilepsies are a very heterogeneous group comprising epilepsies of structural, genetic,&#xD;
      metabolic, immune and infectious etiologies. In daily practice, epilepsy is considered as&#xD;
      structural if lesions are visible on brain MRI in a location consistent with electro-clinical&#xD;
      data. In the absence of visible lesion and clinico-biological arguments for a genetic,&#xD;
      metabolic, immune or infectious cause, these epilepsies can be divided into two groups:&#xD;
      self-limited focal epilepsies (formerly called idiopathic or functional), such as benign&#xD;
      epilepsy with centrotemporal spikes (SLECTS) and secondly epilepsies of unknown causes. This&#xD;
      classification underlines the idea that a lesion might be responsible for the epileptic&#xD;
      disease but could be invisible due to the lack of sensitivity of our current diagnostic&#xD;
      methods, especially in imaging.&#xD;
&#xD;
      The prevalence of patients with non lesional epilepsy defined by MRI is significantly higher&#xD;
      in children (31%) than in adults (21%). Epileptic patients with normal conventional MRI have&#xD;
      a lower chance of having surgery than those with lesions demonstrated by presurgical MRI and,&#xD;
      if so, less chance of becoming seizure-free. It can be challenging to depict brain volume&#xD;
      abnormalities in the pediatric population on MRI. The major challenge is therefore to raise&#xD;
      sensitivity of brain imaging analysis. Voxel-based morphometric MRI post-processing in&#xD;
      MRI-negative epilepsies can be a practical and valuable tool to aid subtle MRI abnormalities&#xD;
      detection and confirm visually identified questionable abnormalities in patients with focal&#xD;
      epilepsy.&#xD;
&#xD;
      In this study, we prospectively included children with suspected focal epilepsy having a&#xD;
      brain MRI using a MP2RAGE sequence and a post-processing morphometric analysis program (MAP)&#xD;
      allowing us to obtain automatically both brain volumetry and T1 relaxometry. The MAP has been&#xD;
      validated with reference ranges in healthy children. Our hypothesis was that the quantitative&#xD;
      information will improve the sensitivity of brain MRI in children with suspected focal&#xD;
      epilepsy. The objectives were to compare the rate of detection of a focal cerebral lesion on&#xD;
      the brain MRI carried out during the exploration of suspected focal epilepsy without then&#xD;
      with the quantitative volumetry and T1 relaxometry obtained in the inclusion center and then&#xD;
      by double anonymized review.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>rate of detection of a focal cerebral lesion on the brain MRI</measure>
    <time_frame>Inclusion visit</time_frame>
    <description>carried out during the exploration of suspected focal epilepsy without then with the quantitative volumetry and T1 relaxometry obtained in the inclusion center and then by double anonymized review</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiologist's confidence level in detecting lesions seen on MRI without the automated quantitative data</measure>
    <time_frame>Inclusion visit</time_frame>
    <description>Measured by a semi-quantitative visual analogue scale in the detection of brain lesions observed on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiologist's confidence level in detecting lesions seen on MRI with the automated quantitative data</measure>
    <time_frame>Inclusion visit</time_frame>
    <description>Measured by a semi-quantitative visual analogue scale in the detection of brain lesions observed on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pediatric brain MRIs interpretation without the additional quantitative brain information</measure>
    <time_frame>Inclusion visit</time_frame>
    <description>Inter-observer agreement in terms of normal or not normal MRI and in case of abnormality, the type of abnormality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pediatric brain MRIs interpretation with the additional quantitative brain information</measure>
    <time_frame>Inclusion visit</time_frame>
    <description>Inter-observer agreement in terms of normal or not normal MRI and in case of abnormality, the type of abnormality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical examination</measure>
    <time_frame>Inclusion visit</time_frame>
    <description>Assessed by weight in kgs and height in cm, International League against epilepsy ( ILAE) classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electroencephalography</measure>
    <time_frame>Inclusion visit</time_frame>
    <description>Assessed by focal abnormalities and area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presentation of brain volumetry and T1 relaxometry in table form and map form</measure>
    <time_frame>Inclusion visit</time_frame>
    <description>pourcentage of choice between the table form and the map form depending on the radiologists</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Focal Epilepsy</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <description>The experimental group will be made up of patients with focal epilepsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pediatric brain MRI</intervention_name>
    <description>Routine brain MRI with automated quantitative information (brain volumetry and T1 relaxometry)</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All participants will be included in a visit as part of their routine follow-up with a&#xD;
        pediatric epilepsy specialist for a work-up including clinical examination, EEG examination&#xD;
        and assessment of symptomatology between clinical, EEG and MRI.&#xD;
&#xD;
        All visits and examinations are part of routine care. Additional quantitative data from the&#xD;
        MRI will not influence medical management in any way.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged 1-18 years&#xD;
&#xD;
          -  Referred or followed by a pediatrician for epilepsy with focal onset&#xD;
&#xD;
          -  Requiring brain MRI as part of the work-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opposition of the child and/or parent to data processing&#xD;
&#xD;
          -  MRI not interpretable&#xD;
&#xD;
          -  Clinical and epileptic data not available or not specifying focus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baptiste Morel</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baptiste Morel</last_name>
    <phone>02 47 47 47 58</phone>
    <email>baptiste.morel@univ-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Louis Marie LEIBER</last_name>
      <phone>02 41 35 36 37</phone>
      <email>lm.leiber@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Louis Marie LEIBER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Chantal DURAND</last_name>
      <phone>04 76 76 75 75</phone>
      <email>cdurand@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Chantal DURAND</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas LEBOUCQ</last_name>
      <phone>04 67 33 67 33</phone>
      <email>n-leboucq@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas LEBOUCQ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bertrand BRUNEAU</last_name>
      <phone>02 99 28 43 21</phone>
      <email>bertrand.bruneau@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand BRUNEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Clocheville</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Baptiste Morel</last_name>
      <phone>02 47 47 47 58</phone>
      <email>baptiste.morel@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Baptiste Morel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain MRI</keyword>
  <keyword>Radiology</keyword>
  <keyword>Pediatry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

